Zacks: Brokerages Anticipate CVS Health Corp (NYSE:CVS) to Announce $1.62 EPS

Analysts predict that CVS Health Corp (NYSE:CVS) will announce earnings per share of $1.62 for the current quarter, according to Zacks Investment Research. Twenty analysts have provided estimates for CVS Health’s earnings, with the highest EPS estimate coming in at $1.73 and the lowest estimate coming in at $1.49. CVS Health also reported earnings per share of $1.62 in the same quarter last year. The company is scheduled to issue its next quarterly earnings results on Wednesday, May 6th.

According to Zacks, analysts expect that CVS Health will report full year earnings of $7.14 per share for the current financial year, with EPS estimates ranging from $7.05 to $7.31. For the next fiscal year, analysts forecast that the business will report earnings of $7.59 per share, with EPS estimates ranging from $7.49 to $7.84. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for CVS Health.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.05. The business had revenue of $66.89 billion during the quarter, compared to analyst estimates of $64.01 billion. CVS Health had a net margin of 2.58% and a return on equity of 14.87%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.14 earnings per share.

CVS has been the topic of several recent analyst reports. Citigroup upped their price objective on shares of CVS Health from $83.00 to $86.00 and gave the company a “buy” rating in a report on Friday. ValuEngine upgraded shares of CVS Health from a “strong sell” rating to a “sell” rating in a report on Friday, January 24th. SunTrust Banks upped their price objective on shares of CVS Health to $85.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Mizuho upped their price objective on shares of CVS Health from $71.00 to $82.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Cfra upped their price objective on shares of CVS Health from $85.00 to $86.00 and gave the company a “strong-buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $78.48.

CVS opened at $71.37 on Wednesday. CVS Health has a 52-week low of $51.72 and a 52-week high of $77.03. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.30. The company has a market cap of $93.67 billion, a P/E ratio of 10.17, a price-to-earnings-growth ratio of 1.54 and a beta of 0.93. The firm’s 50-day moving average price is $72.66 and its 200-day moving average price is $67.66.

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were issued a $0.50 dividend. The ex-dividend date was Wednesday, January 22nd. This represents a $2.00 annualized dividend and a yield of 2.80%. CVS Health’s dividend payout ratio (DPR) is presently 28.25%.

In related news, EVP Karen S. Lynch sold 80,143 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $6,010,725.00. Following the transaction, the executive vice president now owns 41,831 shares in the company, valued at approximately $3,137,325. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Larry J. Merlo sold 266,476 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $74.79, for a total transaction of $19,929,740.04. Following the completion of the transaction, the chief executive officer now owns 703,497 shares in the company, valued at approximately $52,614,540.63. The disclosure for this sale can be found here. In the last quarter, insiders sold 404,182 shares of company stock worth $30,121,266. 0.53% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the stock. YHB Investment Advisors Inc. boosted its position in CVS Health by 7.8% during the 3rd quarter. YHB Investment Advisors Inc. now owns 112,078 shares of the pharmacy operator’s stock valued at $7,069,000 after buying an additional 8,092 shares during the period. Atwater Malick LLC boosted its position in CVS Health by 9.3% during the 3rd quarter. Atwater Malick LLC now owns 51,666 shares of the pharmacy operator’s stock valued at $3,259,000 after buying an additional 4,415 shares during the period. Boenning & Scattergood Inc. boosted its position in CVS Health by 5.1% during the 3rd quarter. Boenning & Scattergood Inc. now owns 86,355 shares of the pharmacy operator’s stock valued at $5,447,000 after buying an additional 4,161 shares during the period. KMG Fiduciary Partners LLC boosted its position in CVS Health by 42.7% during the 3rd quarter. KMG Fiduciary Partners LLC now owns 24,426 shares of the pharmacy operator’s stock valued at $1,541,000 after buying an additional 7,313 shares during the period. Finally, Vishria Bird Financial Group LLC boosted its position in CVS Health by 9.5% during the 3rd quarter. Vishria Bird Financial Group LLC now owns 73,215 shares of the pharmacy operator’s stock valued at $4,618,000 after buying an additional 6,348 shares during the period. Institutional investors own 76.69% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Recommended Story: Liquidity

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.